ICU Medical, Inc.
Description
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
About
CEO
Mr. Vivek Jain
Employees
14,000
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Instruments & Supplies
MIC code
XNGS
Address
951 Calle Amanecer, San Clemente, CA 92673, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 11, 2025 | — | — | — | — |
| Aug 6, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Feb 26, 2025 | — | — | — | — |
| Nov 13, 2024 | 1.25 | 1.59 | 0.34 | 27.20% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 2 | — | 6 |
| Average estimate | — | 1.37 | — | 7.13 |
| Low estimate | — | 1.14 | — | 6.66 |
| High estimate | — | 1.59 | — | 7.46 |
| Last year EPS | — | 0.96 | — | 5.60 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-5.610%
Next qtr. (Mar 2025)
42.190%
Current year
-17.140%
Next year (Dec 2025)
27.280%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 2.26B | 2.28B | 1.32B | 1.27B | 1.27B |
| Cost of revenue | 1.52B | 1.58B | 824.82M | 809.51M | 794.34M |
| Gross profit | 739.87M | 697.76M | 491.49M | 461.50M | 471.86M |
| Operating expense | |||||
| Research & development | 85.34M | 92.98M | 47.50M | 42.95M | 48.61M |
| Selling general and admin | 606.69M | 608.35M | 302.58M | 283.95M | 276.98M |
| Other operating expenses | — | — | 127,000 | -975,000 | 5.74M |
| Operating income | 47.84M | -3.57M | 141.28M | 135.57M | 140.53M |
| Non operating interest income | |||||
| Income | 7.51M | 4.43M | 2.84M | 3.68M | — |
| Expense | 102.73M | 70.81M | 858,000 | 1.75M | 549,000 |
| Other income expense | -30.92M | -44.47M | -20.08M | -40.00M | -25.28M |
| Pretax income | -78.30M | -114.41M | 123.19M | 97.49M | 114.71M |
| Tax provision | -48.64M | -40.12M | 20.05M | 10.62M | 13.67M |
| Net income | -29.66M | -74.29M | 103.14M | 86.87M | 101.04M |
| Basic EPS | -1.23 | -3.11 | 4.86 | 4.16 | 4.90 |
| Diluted EPS | -1.23 | -3.11 | 4.74 | 4.02 | 4.69 |
| Basic average shares | 24.09M | 23.87M | 21.21M | 20.91M | 20.63M |
| Diluted average shares | 24.09M | 23.87M | 21.21M | 20.91M | 20.63M |
| EBITDA | 284.28M | 239.21M | 234.45M | 227.69M | 225.35M |
| Net income from continuing op. | -29.66M | -74.29M | 103.14M | 86.87M | 101.04M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 4.38B | 4.52B | 1.88B | 1.76B | 1.69B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 254.22M | 208.78M | 552.83M | 396.10M | 268.67M |
| Other short term investments | 501,000 | 4.22M | 14.42M | 14.69M | 23.97M |
| Accounts receivable | 161.57M | 221.72M | 105.89M | 124.09M | 202.22M |
| Other receivables | 17.83M | 21.64M | 14.76M | 14.96M | 13.78M |
| Inventory | 709.36M | 696.01M | 290.24M | 314.93M | 337.64M |
| Prepaid assets | 34.04M | 36.23M | 27.24M | 37.01M | 22.55M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | 29.85M | 33.29M | 1.06M | 3.56M | 2.37M |
| Other current assets | 3.67M | 3.53M | 2.23M | 1.82M | 1.99M |
| Non current assets | |||||
| Properties | 556.11M | 527.21M | 443.74M | 441.45M | 399.51M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 636.08M | 559.90M | 431.73M | 397.41M | 309.77M |
| Construction in progress | 117.22M | 152.91M | 72.15M | 53.72M | 101.43M |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -623.89M | -526.44M | -436.74M | -376.47M | -320.16M |
| Goodwill | 3.82B | 3.88B | 275.19M | 263.23M | 273.90M |
| Investment properties | — | — | — | — | — |
| Financial assets | 4.88M | 26.75M | — | — | — |
| Intangible assets | 870.59M | 982.77M | 188.31M | 197.23M | 211.41M |
| Investments and advances | 3.12M | 3.69M | 7.86M | 12.97M | — |
| Other non current assets | 120.61M | 104.40M | 100.44M | 83.59M | 76.98M |
| Total liabilities | 2.26B | 2.43B | 264.71M | 261.43M | 315.14M |
| Current liabilities | |||||
| Accounts payable | 150.03M | 215.90M | 81.13M | 71.86M | 128.63M |
| Accrued expenses | 140.31M | 139.20M | 57.12M | 50.01M | 81.83M |
| Short term debt | 71.16M | 47.86M | 9.01M | 8.74M | 7.36M |
| Deferred revenue | 31.64M | 30.84M | 12.65M | 5.57M | 6.70M |
| Tax payable | 17.49M | 17.84M | 7.77M | 5.99M | 8.73M |
| Pensions | 40.57M | 33.18M | 33.11M | 27.02M | 15.22M |
| Other current liabilities | 7.47M | 1.85M | — | 26.30M | — |
| Non current liabilities | |||||
| Long term debt | 1.63B | 1.69B | 36.04M | 43.41M | 28.90M |
| Provision for risks and charges | 35.06M | 41.80M | 18.02M | 16.44M | 14.46M |
| Deferred liabilities | 55.87M | 126.01M | 1.49M | 1.66M | 2.09M |
| Derivative product liabilities | — | — | 1.48M | — | — |
| Other non current liabilities | 33.93M | 54.36M | 4.27M | 582,000 | 17.89M |
| Shareholders equity | |||||
| Common stock | 2.41M | 2.40M | 2.13M | 2.11M | 2.07M |
| Retained earnings | 807.85M | 837.50M | 911.79M | 808.65M | 721.78M |
| Other shareholders equity | -53.08M | -80.98M | -19.27M | -1.52M | -15.40M |
| Total shareholders equity | 2.12B | 2.09B | 1.62B | 1.50B | 1.38B |
| Additional paid in capital | 1.37B | 1.33B | 721.41M | 693.07M | 668.95M |
| Treasury stock | 262,000 | 243,000 | 27,000 | 39,000 | 157,000 |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||||||
| Net Income | -29.66M | -74.29M | 103.14M | 86.87M | 101.04M | 28.79M | 68.64M | 63.08M | 44.99M | 26.34M | 40.42M | 41.28M | 44.67M | 29.92M | 26.56M | 24.30M | 23.08M | 25.66M | 20.27M | 5.00M | 22.30M | 19.68M | 15.39M | 11.79M | 9.40M | 7.20M | 5.70M | 4.70M | 4.20M | 2.90M | 3.00M | 4.00M | 900,000 |
| Depreciation | 228.77M | 235.15M | 89.70M | 85.63M | 76.92M | 74.74M | 66.57M | 19.05M | 18.07M | 19.45M | 19.51M | 19.00M | 18.29M | 17.35M | 15.67M | 14.22M | 11.80M | 11.23M | 9.70M | 8.60M | 7.36M | 5.29M | 5.03M | 4.61M | 3.90M | 2.40M | 2.10M | 2.00M | 1.80M | 1.10M | 500,000 | 200,000 | 100,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.65M | — | 1.45M | 528,000 | -37,000 | -888,000 | -1.10M | -500,000 | -400,000 | — | 300,000 | — | -400,000 | — | — |
| Stock-Based Compensation | 40.56M | 36.03M | 27.34M | 23.95M | 21.92M | 24.24M | 19.35M | 15.24M | 12.83M | 9.59M | 5.43M | 5.56M | 4.02M | 3.47M | 2.71M | 1.89M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 37.59M | 36.76M | 29.50M | 39.49M | -13.94M | 44.89M | 12.75M | 1.43M | 1.67M | 2.19M | 2.72M | 2.59M | 1.29M | 1.09M | 1,000 | -270,000 | 1.38M | 214,000 | — | 1.98M | 842,000 | 10.19M | 3.76M | — | 100,000 | — | — | — | — | 100,000 | — | -100,000 | -100,000 |
| Accounts Receivable | 48.64M | -19.15M | 13.76M | 78.05M | -23.68M | 20.70M | -149.84M | 744,000 | -20.52M | 4.91M | 3.56M | -5.40M | 6.23M | -6.38M | -9.04M | -12.38M | 523,000 | -2.35M | -14.66M | 15.72M | -8.31M | -3.19M | -637,000 | -5.41M | -600,000 | -3.10M | -300,000 | -300,000 | -600,000 | -600,000 | -100,000 | -700,000 | 100,000 |
| Accounts Payable | -68.30M | 37.47M | 2.35M | -46.42M | -2.70M | 23.27M | 46.65M | -463,000 | 3.12M | -621,000 | -31,000 | -1.54M | 2.67M | -8.22M | 10.38M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -113.13M | -289.12M | 651,000 | -14.91M | -50.15M | -50.85M | 150.10M | -4.79M | -6.72M | 491,000 | -4.09M | 3.79M | 181,000 | -6.48M | 7.53M | 1.04M | 2.11M | -1.93M | 10.67M | -6.97M | 1.62M | -5.86M | 312,000 | 1.94M | 2.80M | 1.30M | 2.10M | -800,000 | 1.00M | -2.00M | -500,000 | -600,000 | 600,000 |
| Operating Cash Flow | 144.48M | -37.15M | 266.42M | 252.67M | 109.40M | 165.78M | 214.22M | 94.30M | 53.43M | 62.34M | 67.50M | 65.29M | 77.36M | 30.75M | 53.81M | 28.81M | 38.89M | 32.83M | 27.63M | 24.34M | 25.25M | 26.65M | 23.82M | 12.04M | 14.50M | 7.30M | 9.20M | 5.60M | 6.70M | 1.50M | 2.50M | 2.80M | 1.60M |
| Investing Activities | |||||||||||||||||||||||||||||||||
| Capital Expenditures | -83.89M | -90.31M | -68.54M | -92.01M | -97.31M | -92.72M | -74.48M | -23.36M | -12.98M | -16.60M | -18.42M | -19.16M | -15.82M | -23.17M | -16.69M | -11.35M | -23.14M | -13.55M | -5.51M | -7.10M | -10.67M | -11.89M | -6.23M | -3.99M | -14.80M | -6.70M | -800,000 | -1.30M | -1.70M | -9.40M | -3.10M | -700,000 | -300,000 |
| Net Intangibles | -9.78M | -9.02M | -12.63M | -8.39M | -8.73M | -8.06M | -5.20M | -1.19M | -951,000 | -989,000 | -1.08M | -1.15M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | -1.84B | -14.45M | — | -76.13M | -1.30M | -162.45M | -2.58M | -27.82M | — | — | — | — | — | -5.66M | — | -3.22M | — | -32.61M | — | -5.88M | -9.48M | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | -3.40M | -13.28M | -32.83M | -26.04M | -30.50M | -24.74M | -118.38M | -56.14M | -93.59M | -86.02M | -98.88M | -90.50M | -23.38M | -99.19M | -62.95M | -38.86M | -43.72M | -60.41M | -23.63M | — | -15.17M | -20.29M | — | -500,000 | -3.90M | -2.50M | — | — | -1.00M | -1.80M | — | — |
| Sale of Investments | 4.22M | 36.43M | 18.00M | 28.90M | 41.29M | 15.44M | — | 158.53M | 83.05M | 89.43M | 92.35M | 77.80M | 41.61M | 64.67M | 107.21M | 83.27M | 54.86M | 19.85M | 62.25M | 13.25M | 12.95M | — | — | -12.30M | — | — | — | 500,000 | 4.00M | 8.00M | — | — | — |
| Investing Cash Flow | -78.17M | -1.90B | -78.06M | -89.75M | -158.16M | -95.31M | -261.67M | 17.47M | -10.29M | -20.76M | -12.04M | -40.23M | -45.73M | 19.63M | -37.76M | 3.61M | -10.30M | -34.55M | -33.63M | -14.82M | -12.51M | -36.55M | -26.52M | -16.29M | -15.30M | -10.50M | -3.30M | -2.80M | 2.30M | -2.40M | -4.90M | -13.40M | -300,000 |
| Financing Activities | |||||||||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | 1.66B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -30.65M | -23.06M | -607,000 | -150.36M | — | — | -75.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -9.35M | -13.06M | -25.64M | -12.88M | -18.64M | -6.25M | — | — | 9.33M | 5.70M | 6.97M | 4.57M | 4.29M | 1.68M | 101,000 | 10.37M | 551,000 | 6.51M | — | — | — | — | — | — | 100,000 | — | — | — | — | — | — | — | -2.30M |
| Financing Cash Flow | -40.00M | 1.63B | -26.24M | -163.23M | -37.28M | -12.50M | -76.35M | -14.87M | 9.97M | 2.35M | 6.39M | 6.79M | -7.67M | -26.97M | -20.34M | 4.51M | -36.96M | 9.28M | 7.66M | -6.94M | -12.70M | 8.72M | 4.15M | 3.58M | 400,000 | 3.10M | -4.50M | -3.60M | 16.80M | 300,000 | 600,000 | 10.70M | -2.30M |
| Other Cash Details | |||||||||||||||||||||||||||||||||
| End Cash Position | 254.22M | 208.78M | 552.83M | 396.10M | 268.67M | 344.78M | 290.07M | 445.08M | 336.16M | 275.81M | 226.02M | 146.90M | 99.59M | 78.85M | 51.25M | 55.70M | 7.87M | 13.15M | 6.85M | 5.62M | 1.79M | 4.17M | 3.90M | 1.95M | 1.90M | — | — | — | — | — | — | — | — |
| Income Tax Paid | 35.81M | 27.50M | 19.56M | 31.63M | 9.68M | 12.60M | 5.11M | 21.10M | 23.00M | 8.67M | 12.17M | 16.74M | 20.11M | 15.25M | 9.03M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 95.91M | 63.71M | 858,000 | 1.75M | 549,000 | 709,000 | 2.05M | 118,000 | 39,000 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 72.53M | -161.46M | 186.37M | 122.36M | -4.12M | 59.44M | 74.74M | 65.39M | 50.26M | 48.75M | 46.23M | 45.97M | 48.66M | 9.92M | 34.45M | 18.88M | 17.87M | 12.00M | 21.86M | 18.18M | 12.16M | 16.20M | 18.10M | 8.77M | — | -100,000 | 7.90M | 5.20M | 5.30M | -8.50M | 200,000 | 2.30M | 2.70M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | Nov 30, 2024 | 1,581,897 | 254.67M | 6.46% |
| Janus Henderson Enterprise Fund | Sep 30, 2024 | 1,230,753 | 198.14M | 5.03% |
| Undiscovered Managers Behavioral Value Fund | Sep 30, 2024 | 1,216,453 | 195.84M | 4.97% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 726,732 | 117.00M | 2.97% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 601,023 | 96.76M | 2.45% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 580,749 | 93.49M | 2.37% |
| Janus Henderson Triton Fund | Sep 30, 2024 | 451,026 | 72.61M | 1.84% |
| Vanguard Small Cap Value Index Fund | Sep 30, 2024 | 393,208 | 63.30M | 1.61% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 359,666 | 57.90M | 1.47% |
| Fidelity Select Portfolios - Medical Technology & Devices Port | Nov 30, 2024 | 350,000 | 56.35M | 1.43% |
Article
New Strong Buy Stocks for January 14th
BWAY, EE, MATW, BRBR and FMAO have been added to the Zacks Rank #1 (Strong Buy) List on January 14, 2025.
Jan 14, 2025
Article
ICU Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN CLEMENTE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ICU Medical's presentation will be on Wednesday, January 15, 2025 at 10:30 a.m. PT (1:30 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, January 15, 2025 and Thursday, January 16, 2025.
Jan 3, 2025
Article
ICU Medical Inc. (ICUI) Q3 2024 Earnings Call Transcript
ICU Medical Inc. (NASDAQ:ICUI ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants John Mills - ICR Vivek Jain - Chief Executive Officer and Chairman Brian Bonnell - Chief Financial Officer Conference Call Participants Brett Fishbin - KeyBanc Eric Fleming - Raymond James Larry Solow - CJS Securities Kristen Stewart - CL King Mike Matson - Needham and Company Michael Toomey - Jefferies Operator Good day, everyone, and welcome to today's ICU Medical Inc.'s Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Nov 13, 2024
